{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:05:46Z","timestamp":1791806746162,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFS0375"],"award-info":[{"award-number":["2021YFS0375"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC1935"],"award-info":[{"award-number":["2024NSFSC1935"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373189"],"award-info":[{"award-number":["82373189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112492","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:51:31Z","timestamp":1718891491000},"page":"112492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma"],"prefix":"10.1016","volume":"137","author":[{"given":"Beichuan","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangyou","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Yee Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9191-7708","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10360","key":"10.1016\/j.intimp.2024.112492_b0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.intimp.2024.112492_b0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10126","key":"10.1016\/j.intimp.2024.112492_b0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.intimp.2024.112492_b0025","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000523702","article-title":"Durvalumab plus tremelimumab: a novel combination immunotherapy for unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"issue":"27","key":"10.1016\/j.intimp.2024.112492_b0035","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112492_b0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112492_b0045","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","article-title":"Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study","volume":"15","author":"Fu","year":"2021","journal-title":"Hep. Intl."},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12072-019-09929-4","article-title":"The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting","volume":"13","author":"Obi","year":"2019","journal-title":"Hep. Intl."},{"issue":"3","key":"10.1016\/j.intimp.2024.112492_b0055","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12072-022-10480-y","article-title":"Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients","volume":"17","author":"Yang","year":"2023","journal-title":"Hep. Intl."},{"issue":"3","key":"10.1016\/j.intimp.2024.112492_b0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.112492_b0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2024.112492_b0070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver cancer"},{"issue":"11","key":"10.1016\/j.intimp.2024.112492_b0075","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1097\/JS9.0000000000000654","article-title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study","volume":"109","author":"Deng","year":"2023","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial.","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112492_b0085","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4251\/wjgo.v15.i1.1","article-title":"Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma","volume":"15","author":"Liang","year":"2023","journal-title":"World J. Gastrointestinal Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112492_b0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.soc.2023.06.003","article-title":"Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma","volume":"33","author":"Bejjani","year":"2024","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"3","key":"10.1016\/j.intimp.2024.112492_b0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000367739","article-title":"Surgical and locoregional therapy of HCC: TACE","volume":"4","author":"Tsurusaki","year":"2015","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0110","doi-asserted-by":"crossref","first-page":"e057","DOI":"10.1097\/AS9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann. Surgery Open"},{"key":"10.1016\/j.intimp.2024.112492_b0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112492_b0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jimed.2021.05.002","article-title":"Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy","volume":"4","author":"Xue","year":"2021","journal-title":"J. Interventional Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies.","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"2","key":"10.1016\/j.intimp.2024.112492_b0145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"6","key":"10.1016\/j.intimp.2024.112492_b0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.intimp.2024.112492_b0155","unstructured":"[Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)]. Zhonghua yi xue za zhi, 2023, 103(34): 2674-2694."},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112492_b0165","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1159\/000508724","article-title":"Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma","volume":"9","author":"Ueshima","year":"2020","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112492_b0180","doi-asserted-by":"crossref","first-page":"1004652","DOI":"10.3389\/fonc.2022.1004652","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.112492_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.919069","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma","volume":"9","author":"Xu","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.112492_b0190","doi-asserted-by":"crossref","first-page":"1127349","DOI":"10.3389\/fimmu.2023.1127349","article-title":"Hepatic arterial infusion chemotherapy combined with anti-PD-1\/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112492_b0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2024.112492_b0200","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1568009623666230215142941","article-title":"Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.","volume":"23","author":"Chen","year":"2023","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.intimp.2024.112492_b0205","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"The Lancet Oncology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:57:19Z","timestamp":1778619439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924010130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"alternative-id":["S1567576924010130"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112492","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112492"}}